Codex DNA Financials
| DNAYDelisted Stock | USD 1.30 0.10 8.33% |
With this module, you can analyze Codex financials for your investing period. You should be able to track the changes in Codex DNA individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Codex |
Understanding current and past Codex DNA Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Codex DNA's financial statements are interrelated, with each one affecting the others. For example, an increase in Codex DNA's assets may result in an increase in income on the income statement.
The data published in Codex DNA's official financial statements usually reflect Codex DNA's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Codex DNA. For example, before you start analyzing numbers published by Codex accountants, it's critical to develop an understanding of what Codex DNA's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Codex DNA's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Codex DNA's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Codex DNA's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Codex DNA. Please utilize our Beneish M Score to check the likelihood of Codex DNA's management manipulating its earnings.
Codex DNA Stock Summary
Codex DNA competes with PennantPark Investment, BJs Restaurants, Cheesecake Factory, LuxUrban Hotels, and Royal Bank. Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California. Codex Dna operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US1920031010 |
| Business Address | 9535 Waples Street, |
| Sector | Healthcare |
| Industry | Medical Devices |
| Benchmark | NYSE Composite |
| Website | codexdna.com |
| Phone | 858 228 4115 |
| Currency | USD - US Dollar |
You should never invest in Codex DNA without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Codex Stock, because this is throwing your money away. Analyzing the key information contained in Codex DNA's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Codex DNA Key Financial Ratios
Generally speaking, Codex DNA's financial ratios allow both analysts and investors to convert raw data from Codex DNA's financial statements into concise, actionable information that can be used to evaluate the performance of Codex DNA over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Codex DNA reports annually and quarterly.Codex Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Codex DNA's current stock value. Our valuation model uses many indicators to compare Codex DNA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Codex DNA competition to find correlations between indicators driving Codex DNA's intrinsic value. More Info.Codex DNA is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Codex DNA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Codex DNA's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Codex DNA's earnings, one of the primary drivers of an investment's value.Codex DNA Market Pulse
| Quote | 1.30 |
| Change(%) | 8.33 |
| Change | 0.10 |
| Open | 1.2 |
| Low | 1.2 |
| High | 1.31 |
| Volume | 0 |
| Exchange | NASDAQ |
About Codex DNA Financials
What exactly are Codex DNA Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Codex DNA's income statement, its balance sheet, and the statement of cash flows. Potential Codex DNA investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Codex DNA investors may use each financial statement separately, they are all related. The changes in Codex DNA's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Codex DNA's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Codex DNA Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Codex DNA is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Codex has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Codex DNA's financials are consistent with your investment objective using the following steps:- Review Codex DNA's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Codex DNA's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Codex DNA's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Codex DNA's stock is overvalued or undervalued.
Codex DNA April 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Codex DNA help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Codex DNA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Codex DNA based on widely used predictive technical indicators. In general, we focus on analyzing Codex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Codex DNA's daily price indicators and compare them against related drivers.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 19.39 | |||
| Value At Risk | (7.45) | |||
| Potential Upside | 6.21 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Codex DNA information on this page should be used as a complementary analysis to other Codex DNA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Codex Stock
If you are still planning to invest in Codex DNA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Codex DNA's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |